DFL24498 Clinical Trials (2026): 2 Studies for Atopic Keratoconjunctivitis & Dry Eye Disease (DED)

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: .

2 DFL24498 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 2 indications (including Atopic Keratoconjunctivitis & Dry Eye Disease (DED)) and 555 total planned enrollment. 1 Phase 3 DFL24498 trial and 1 Phase 2 are listed. 2 DFL24498 clinical trials are actively recruiting at 8 U.S. sites across 7 states. Most recent activity: NCT07395232 (May 2027).

Where to Participate: All DFL24498 Trial Sites in the U.S. (8 sites across 7 states)

Every actively recruiting DFL24498trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

StateFacilityCityTrialMap
FLBowden Eye Associates - Southside LocationJacksonville32256NCT07395232Map
FLUniversity of Miami, Miller School of Medicine, Bascom Palmer Eye InstituteMiami33136NCT07395232Map
GAClayton Eye Clinical ResearchMorrow30260NCT07395232Map
MOOphthalmology AssociatesSt Louis63131NCT07395232Map
NYNYU Langone Health - Eye CenterNew York10017NCT07395232Map
NCDuke Eye Center - OphthalmologyDurham27710NCT07395232Map
TNTotal Eye Care, PAMemphis38119NCT07395232Map
TXBaylor University Jamail Specialty Care Center- Alkek Eye Center- OphthalmologyHouston77030NCT07395232Map

DFL24498 clinical trials at a glance: phase × recruitment status

Phaserecruitingnot yet recruitingTotal
P211
P311

Recruiting DFL24498 clinical trials (2)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT IDTitlePhaseIndicationEnrollmentStarted
NCT07395232An Efficacy and Safety Study of DFL24498 in the Treatment of AKCP3Atopic Keratoconjunctivitis138Dec 2025
NCT07503886An Exploratory Efficacy and Safety Study of DFL24498 Topical Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye DiseaseP2Dry Eye Disease (DED)417May 2026

DFL24498 clinical trials by indication

Dry Eye Disease (DED) (1)

NCTAcronymPhaseStatusTitle
NCT07503886P2not yet recruitingAn Exploratory Efficacy and Safety Study of DFL24498 Topical Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye Disease

Atopic Keratoconjunctivitis (1)

NCTAcronymPhaseStatusTitle
NCT07395232P3recruitingAn Efficacy and Safety Study of DFL24498 in the Treatment of AKC

All DFL24498 trials (2)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT IDAcronymTitlePhaseStatusEnrollmentSponsorStarted
NCT07395232An Efficacy and Safety Study of DFL24498 in the Treatment of AKCP3recruiting138Dompé Farmaceutici S.p.ADec 2025
NCT07503886An Exploratory Efficacy and Safety Study of DFL24498 Topical Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye DiseaseP2not yet recruiting417Dompé Farmaceutici S.p.AMay 2026

DFL24498 clinical trials: frequently asked questions

How many DFL24498 clinical trials are there?
2 DFL24498 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
Are DFL24498 clinical trials recruiting in 2026?
Yes — 1 DFL24498 trial is actively recruiting in 2026, with 8 U.S. sites across 7 states. See the recruiting trials and the per-state site list further down this page.
What conditions is DFL24498 being studied for?
DFL24498 is being studied for Atopic Keratoconjunctivitis, Dry Eye Disease (DED). The trials are grouped by indication on this page.
What phase is DFL24498 in?
DFL24498 clinical trials span 1 Phase 3, 1 Phase 2. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors DFL24498 clinical trials?
The lead sponsor across the most DFL24498 trials is Dompé Farmaceutici S.p.A. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming DFL24498as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed .

Related pages on Hipa.ai: